乙和危急病患者中心房的风险:来自eICU数据库的多中心研究
ZhiMing Huang1, Weichao Li1, WeiXian Xie1
1Department of Anesthesiology, Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, Guangdong, China.
Frontiers in pharmacology
|April 10, 2025
概括
在重症患者中使用烯与患上新的心房动 (AF) 的风险更高有关. 这一发现表明,烯是重症监护机构中AF的可修改风险因素.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 血管压缩剂对于危急病患者的血压管理至关重要.
- 人们担心血管压缩剂的副作用,包括心律失常和心肌氧气平衡受损.
- 以前的研究并没有明确地确定基和新发动的心房动 (AF) 之间的联系.
研究的目的:
- 为了研究费尼莱弗林 (phenylephrine) 给药与严重病情的成年人中新发性心房 (AF) 的发生率之间的关联.
- 评估使用烯和发展AF的风险之间的药理关系.
主要方法:
- 对eICU数据库的多中心回顾分析.
- 使用倾向分数匹配 (PSM) 来创建暴露在和未暴露患者中的平衡队列.
- 考克斯比例危险模型 (未调整和调整) 用于评估烯和AF之间的关联.
主要成果:
- 这项研究包括51,294名严重病情严重的成年人.
- 在PSM之后,2,110名暴露于烯的患者与6,330名对照人群进行了比较.
- 与对照组 (4.9%,p < 0.001) 相比,暴露于烯的患者出现新的AF的发生率显著更高 (10.5%).
- 乙二烯的使用与29%的新发肌痛风险增加有关 (aHR,1.29;95% CI,1.05-1.58).
- 这种关联在所有灵敏度分析中保持一致.
结论:
- 烯被确定为重症监护中新发性AF的潜在可修改风险因素.
- 这些发现支持对血管压缩剂的选择采取更谨慎的方法,包括对益处和危害的评估.
- 需要在临床上做出风险意识的临床决策,以考虑烯的使用情况.
相关概念视频
01:30Adrenergic Agonists: Therapeutic Uses
693
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
693
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
665
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
665
01:17Imaging Studies for Cardiovascular System I:Echocardiography
273
Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
273
01:28Adrenergic Agonists: Mixed-Action Agents
631
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
631
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
01:16ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
153
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
153